Surmodics, Inc. (SRDX): Price and Financial Metrics


Surmodics, Inc. (SRDX): $36.02

-0.31 (-0.85%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SRDX POWR Grades

  • Stability is the dimension where SRDX ranks best; there it ranks ahead of 78.91% of US stocks.
  • The strongest trend for SRDX is in Growth, which has been heading up over the past 179 days.
  • SRDX's current lowest rank is in the Growth metric (where it is better than 11.24% of US stocks).

SRDX Stock Summary

  • The ratio of debt to operating expenses for SURMODICS INC is higher than it is for about just 15.46% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, SURMODICS INC is reporting a growth rate of -411.8%; that's higher than just 4.06% of US stocks.
  • Revenue growth over the past 12 months for SURMODICS INC comes in at -5.57%, a number that bests merely 17.02% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to SRDX, based on their financial statements, market capitalization, and price volatility, are HCWB, ONTX, KOPN, OVID, and NVCN.
  • SRDX's SEC filings can be seen here. And to visit SURMODICS INC's official web site, go to www.surmodics.com.

SRDX Valuation Summary

  • In comparison to the median Healthcare stock, SRDX's price/sales ratio is 1.03% higher, now standing at 4.9.
  • Over the past 243 months, SRDX's price/earnings ratio has gone down 142.9.

Below are key valuation metrics over time for SRDX.

Stock Date P/S P/B P/E EV/EBIT
SRDX 2022-11-01 4.9 3.8 -37.1 -29.6
SRDX 2022-10-31 4.9 3.8 -37.2 -29.8
SRDX 2022-10-28 4.8 3.8 -36.6 -29.3
SRDX 2022-10-27 4.6 3.6 -35.4 -28.2
SRDX 2022-10-26 4.6 3.6 -34.9 -27.9
SRDX 2022-10-25 4.4 3.5 -33.8 -27.0

SRDX Growth Metrics

    The 5 year revenue growth rate now stands at 38.59%.
  • Its 4 year net income to common stockholders growth rate is now at -32.15%.
  • Its 3 year net income to common stockholders growth rate is now at -462.05%.
Over the past 49 months, SRDX's revenue has gone up $19,578,000.

The table below shows SRDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 97.934 -13.834 -12.835
2022-03-31 96.953 -7.582 -10.471
2021-12-31 105.842 12.633 1.699
2021-09-30 105.136 15.389 4.237
2021-06-30 103.708 15.814 1.58
2021-03-31 106.718 24.498 7.326

SRDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SRDX has a Quality Grade of B, ranking ahead of 94.57% of graded US stocks.
  • SRDX's asset turnover comes in at 0.604 -- ranking 71st of 186 Medical Equipment stocks.
  • MMSI, POAI, and OSUR are the stocks whose asset turnover ratios are most correlated with SRDX.

The table below shows SRDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.604 0.837 0.071
2021-03-31 0.632 0.848 0.115
2020-12-31 0.578 0.832 -0.017
2020-09-30 0.588 0.839 -0.016
2020-06-30 0.648 0.854 0.060
2020-03-31 0.648 0.861 0.063

SRDX Price Target

For more insight on analysts targets of SRDX, see our SRDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $76.25 Average Broker Recommendation 1.25 (Strong Buy)

SRDX Stock Price Chart Interactive Chart >

Price chart for SRDX

SRDX Price/Volume Stats

Current price $36.02 52-week high $50.85
Prev. close $36.33 52-week low $28.27
Day low $35.76 Volume 5,300
Day high $36.27 Avg. volume 41,772
50-day MA $32.04 Dividend yield N/A
200-day MA $36.88 Market Cap 503.92M

Surmodics, Inc. (SRDX) Company Bio


SurModics Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The company was founded in 1979 and is based in Eden Prairie, Minnesota.


SRDX Latest News Stream


Event/Time News Detail
Loading, please wait...

SRDX Latest Social Stream


Loading social stream, please wait...

View Full SRDX Social Stream

Latest SRDX News From Around the Web

Below are the latest news stories about SURMODICS INC that investors may wish to consider to help them evaluate SRDX as an investment opportunity.

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SurModics (SRDX – Research Report) and Axsome Therapeutics (AXSM – Research Report) with bullish sentiments. SurModics (SRDX) In a report released today, Michael Petusky from Barrington maintained a Buy rating on SurModics, with a price target of $70.00. The company's shares closed last Thursday at $32.86. According to TipRanks.

Christine Brown on TipRanks | November 18, 2022

Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium

EDEN PRAIRIE, Minn., November 17, 2022--Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium

Yahoo | November 17, 2022

Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16

EDEN PRAIRIE, Minn., November 11, 2022--Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16

Yahoo | November 11, 2022

Surmodics Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags

Surmodics ( NASDAQ:SRDX ) Full Year 2022 Results Key Financial Results Revenue: US$100.0m (down 4.9% from FY 2021). Net...

Yahoo | November 11, 2022

Barrington Reaffirms Their Buy Rating on SurModics (SRDX)

In a report released today, Michael Petusky from Barrington maintained a Buy rating on SurModics (SRDX - Research Report), with a price target of $70.00. The company's shares closed yesterday at $32.05.Petusky covers the Healthcare sector, focusing on stocks such as Landec, US Physical Therapy, and Haemonetics. According to TipRanks, Petusky has an average return of 7.1% and a 49.85% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SurModics with a $58.00 average price target, which is an 80.97% upside from current levels.

Jason Carr on TipRanks | November 10, 2022

Read More 'SRDX' Stories Here

SRDX Price Returns

1-mo 11.10%
3-mo 5.54%
6-mo N/A
1-year -21.30%
3-year -11.91%
5-year 11.34%
YTD -25.19%
2021 10.64%
2020 5.04%
2019 -12.34%
2018 68.79%
2017 10.24%

Continue Researching SRDX

Here are a few links from around the web to help you further your research on Surmodics Inc's stock as an investment opportunity:

Surmodics Inc (SRDX) Stock Price | Nasdaq
Surmodics Inc (SRDX) Stock Quote, History and News - Yahoo Finance
Surmodics Inc (SRDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8054 seconds.